Over the summer 23andMe launched a collaborative study with Pfizer to study the research inflammatory bowel disease (IBD).

We’ve been encouraged by the number of people diagnosed with either Crohn’s disease and ulcerative colitis who have joined the study.

On top of the research we’re doing, we also want to raise awareness about these debilitating digestive conditions and Inflammatory Bowel Disease (IBD) more broadly.
More than 1.4 million Americans suffer from IBD, while in Europe two in every 1,000 people are affected. The incidence and prevalence of IBD, is rising even in Asia where the rates have historically been low. Not to be confused with irritable bowel syndrome, IBD is a very serious and sometimes crippling condition. Symptoms can include abdominal pain, persistent diarrhea, bleeding, and severe weight loss.
In order to participate in the first study within the IBD community, you must meet all six criteria below: 
Eligible Individuals
1. You’ve been diagnosed with Crohn’s disease or ulcerative colitis by a qualified physician.
2. You’re willing to submit a saliva sample for DNA testing and complete online surveys related to your condition.
3. You have access to the internet.
4. You are at least 6 years old (minors under 18 require parental consent to enroll).
5. You are not a current 23andMe customer.*
6. You reside in the United States.
*If you are a current 23andMe customer, learn how you can participate here.

Learn more and join the IBD study today: www.23andme.com/ibd
The preceding article is content provided by our sponsor 23andMe.com. The views and opinions expressed in the content above are not the views and opinions of IBD News Today or its parent company, BioNews Services, LLC.